BRUKER CORP

Bruker Corporation announced its second quarter 2026 financial results, reporting revenues of $838.5 million, a 5.2% increase year-over-year, with organic growth of 2.8%. The company posted a GAAP diluted loss per share of $(0.41), primarily due to $134.9 million in goodwill impairment charges, but achieved non-GAAP diluted EPS of $0.49. Bruker Scientific Instruments (BSI) saw strong organic bookings growth of 10%. The company updated its full-year 2026 guidance for currency and tax only, projecting revenues of $3.54 billion to $3.57 billion and non-GAAP EPS of $2.10 to $2.15.

Bruker Corporation's Board of Directors declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. The dividend was declared on July 30, 2026. It is payable on September 1, 2026, to shareholders of record at the close of business on August 15, 2026.

Bruker Corporation announced that its Board of Directors declared a quarterly cash dividend of $0.05 per share on the company's common stock. The dividend was declared on May 14, 2026. It is scheduled to be paid on July 7, 2026, to shareholders who are on record as of the close of business on June 22, 2026.

Bruker Corporation reported Q1 2026 total revenue of $823.4 million, a 2.7% increase compared to $801.4 million in Q1 2025. However, net income attributable to common shareholders significantly decreased to $3.5 million, or $0.02 per diluted share, from $17.4 million, or $0.11 per diluted share, in the prior year period. The company completed the acquisition of the remaining 60% ownership in Tofwerk AG, which contributed to a non-taxable gain of $12.2 million from a previously held equity interest.

Bruker Corporation announced its first quarter 2026 financial results, reporting revenues of $823.4 million, a 2.7% increase year-over-year, though organic revenue decreased by 4.4%. GAAP diluted EPS fell to $0.02 from $0.11 in Q1 2025, and non-GAAP diluted EPS was $0.31, down from $0.47. Despite the Q1 pressures, the company saw healthy bookings for its Bruker Scientific Instruments (BSI) segment, with a book-to-bill ratio above 1.0x. Bruker reconfirmed its full-year 2026 guidance, expecting a return to organic revenue growth in Q2 and double-digit EPS growth for the full fiscal year.

Bruker Corporation's Board of Directors declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. The dividend was declared on April 28, 2026, and is payable on June 1, 2026, to shareholders of record as of May 15, 2026.

Falko Busse, Ph.D., an executive officer of Bruker Corporation and President of its wholly owned subsidiary Bruker BioSpin Group, will transition from his duties around May 1, 2026, with his employment officially terminating on October 31, 2026. In connection with his departure, Dr. Busse will receive separation benefits, including severance, a pro-rated bonus, and unused vacation payout, totaling approximately $1,020,351. However, he will forfeit any unvested equity awards he holds on the separation date.